OTCMKTS:GMXAY - GENMAB A/S/S Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$31.75
▲ +0.83 (2.68%)
1 month | 3 months | 12 months
Get New GENMAB A/S/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMXAY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMXAY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for GENMAB A/S/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $31.75.
N/A
The current consensus among 0 investment analysts is to n/a stock in GENMAB A/S/S. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/27/2019UBS GroupReiterated RatingBuy ➝ Neutral
i
1/2/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
12/10/2018Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
i
10/1/2018HC WainwrightInitiated CoverageBuy
i
9/10/2018Bank of AmericaDowngradeNeutral ➝ Underperform
i
6/20/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
6/21/2016JPMorgan Chase & Co.Initiated CoverageNeutral
i
(Data available from 3/8/2016 forward)
GENMAB A/S/S logo
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.
Read More

Today's Range

Now: $31.75
$30.18
$31.76

50 Day Range

MA: $36.82
$18.35
$44.40

52 Week Range

Now: $31.75
$12.10
$19.00

Volume

1,018,266 shs

Average Volume

48,553 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of GENMAB A/S/S?

The following Wall Street analysts have issued research reports on GENMAB A/S/S in the last year:
View the latest analyst ratings for GMXAY.

What is the current price target for GENMAB A/S/S?

0 Wall Street analysts have set twelve-month price targets for GENMAB A/S/S in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GENMAB A/S/S in the next year.
View the latest price targets for GMXAY.

What is the current consensus analyst rating for GENMAB A/S/S?

GENMAB A/S/S currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GMXAY.

What other companies compete with GENMAB A/S/S?

How do I contact GENMAB A/S/S's investor relations team?

The company's listed phone number is 45 70 20 27 28. The official website for GENMAB A/S/S is www.genmab.com.